Momelotinib Dose-Intensity is Maintained in JAK Inhibitor-Naive and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients
Por:
Gupta, V, Egyed, M, Hus, M, Kirgner, I, Lech-Maranda, E, Mayer, J, Mead, A, McLornan, D, Nagy, Z, Oh, S, Platzbecker, U, Ross, D, Trelinski, J, Verstovsek, S, Xicoy, B, Yoon, SS, Smith, G, Kowalski, M and Mesa, R
Publicada:
1 sep 2020
Resumen:
Filiaciones:
Gupta, V:
Princess Margaret Canc Ctr, Toronto, ON, Canada
Egyed, M:
Somogy Cty Mor Kaposi Gen Hosp, Dept Hematol, Kaposvar, Hungary
Hus, M:
Dept Hematooncol & Bone Marrow Transplantat, Lublin, Poland
Kirgner, I:
Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
Lech-Maranda, E:
Inst Hematol & Tranfus Med, Dept Hematol, Warsaw, Poland
Mayer, J:
Masaryk Univ Hosp Brno, Brno, Czech Republic
Mead, A:
Oxford Univ Hosp, Oxford, England
McLornan, D:
Guys & St Thomas NHS Fdn Trust, London, England
Nagy, Z:
Semmelweis Univ, Budapest, Hungary
Oh, S:
Washington Univ, St Louis, MO 63110 USA
Platzbecker, U:
Leipzig Univ Hosp, Leipzig, Germany
Ross, D:
Flinders Med Ctr, Bedford Pk, SA, Australia
Trelinski, J:
Med Univ Lodz, Lodz, Poland
Verstovsek, S:
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Onocl, Barcelona, Spain
Yoon, SS:
Seoul Natl Univ Hosp, Seoul, South Korea
Smith, G:
Sierra Oncol Inc, Vancouver, BC, Canada
Kowalski, M:
Sierra Oncol Inc, Vancouver, BC, Canada
Mesa, R:
UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
|